Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junxiang Luo

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Nature|April 3, 2024
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemiaDwight Koeberl, Andreas Schulze, Neal Sondheimer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 23, 2025
Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trialsRui Li, Xiaofeng Wang, Junxiang Luo, et al.
Journal of Cardiovascular Pharmacology|January 27, 2011
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology dataBaojin Zhu, Mark B Effron, M Pandurang Kulkarni, et al.
Journal of Clinical Pharmacology|June 2, 2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudyJeffrey S Riesmeyer, Daniel E Salazar, Govinda J Weerakkody, et al.
Thrombosis and Haemostasis|January 12, 2010
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO studyGilles Montalescot, Georgios Sideris, Remy Cohen, et al.
Cell Reports|March 19, 2026
De novo fast motion computation in the primate visual cortexKeyan He, Lixuan Liu, Junxiang Luo, et al.
Journal of the American College of Cardiology|October 23, 2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trialDavid Erlinge, Jurrien Ten Berg, David Foley, et al.
Journal of the American College of Cardiology|June 11, 2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patientsDavid Erlinge, Paul A Gurbel, Stefan James, et al.
Orphanet Journal of Rare Diseases|March 10, 2026
Characterizing the frequency of clinical events and assessing biomarkers in propionic acidemia: a natural history studyBernd C Schwahn, Gerard T Berry, Hilary J Vernon, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Nature|April 3, 2024
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemiaDwight Koeberl, Andreas Schulze, Neal Sondheimer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 23, 2025
Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trialsRui Li, Xiaofeng Wang, Junxiang Luo, et al.
Journal of Cardiovascular Pharmacology|January 27, 2011
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology dataBaojin Zhu, Mark B Effron, M Pandurang Kulkarni, et al.
Journal of Clinical Pharmacology|June 2, 2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudyJeffrey S Riesmeyer, Daniel E Salazar, Govinda J Weerakkody, et al.
Thrombosis and Haemostasis|January 12, 2010
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO studyGilles Montalescot, Georgios Sideris, Remy Cohen, et al.
Cell Reports|March 19, 2026
De novo fast motion computation in the primate visual cortexKeyan He, Lixuan Liu, Junxiang Luo, et al.
Journal of the American College of Cardiology|October 23, 2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trialDavid Erlinge, Jurrien Ten Berg, David Foley, et al.
Journal of the American College of Cardiology|June 11, 2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patientsDavid Erlinge, Paul A Gurbel, Stefan James, et al.
Orphanet Journal of Rare Diseases|March 10, 2026
Characterizing the frequency of clinical events and assessing biomarkers in propionic acidemia: a natural history studyBernd C Schwahn, Gerard T Berry, Hilary J Vernon, et al.
Pageof 4